By Budi Oetomo Narendra 
Researchers at Oregon Health & Science University (OHSU) have achieved a significant milestone in the fight against cancer, developing a novel molecule, SU212, that demonstrates considerable promise in treating difficult cases of triple-negative breast cancer (TNBC). This particularly aggressive form of the disease currently presents formidable challenges due to its limited effective treatment options. The findings, detailed in a recent study published in the prestigious journal Cell Reports Medicine, illuminate a new therapeutic pathway by targeting an enzyme crucial for cancer progression, offering a glimmer of hope for patients facing this challenging diagnosis and potentially other forms of cancer influenced by similar mechanisms.
The Unmet Need in Triple-Negative Breast Cancer
Triple-negative breast cancer accounts for approximately 10-15% of all breast cancer diagnoses, yet it represents a disproportionately high burden of morbidity and mortality. Unlike other breast cancer subtypes, TNBC cells lack the three most common receptors that doctors target with therapy: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This "triple-negative" status means that hormone therapy and HER2-targeted drugs, which are highly effective for other breast cancers, are rendered useless against TNBC. Consequently, treatment for TNBC primarily relies on conventional chemotherapy, surgery, and radiation therapy. While these treatments can be effective for some patients, TNBC is notorious for its aggressive nature, higher rates of recurrence, and a poorer prognosis compared to other breast cancer types. It disproportionately affects younger women and women of African American and Hispanic descent, adding a layer of health equity concern to the urgency of finding better treatments. The lack of specific molecular targets has long been a significant barrier to developing targeted therapies, leaving a critical unmet need in oncology.
SU212: A New Strategy Targeting Cancer Metabolism
The OHSU team’s experimental molecule, SU212, introduces a novel strategy by directly interfering with a fundamental metabolic process that many cancer cells exploit for their rapid growth and survival. At the heart of this mechanism is an enzyme called enolase 1, or ENO1. In healthy cells, ENO1 plays a vital role in glycolysis, the metabolic pathway that converts glucose into energy. However, cancer cells often exhibit an altered metabolism, known as the Warburg effect, where they preferentially rely on glycolysis even in the presence of oxygen, a less efficient but faster way to produce energy and building blocks for rapid proliferation. Many cancer cells, including those in TNBC, produce ENO1 in unusually high amounts to fuel this accelerated metabolism.
SU212 functions by attaching specifically to the ENO1 enzyme. Once bound, the molecule initiates a process that causes the enzyme to break down, effectively disabling its function. By disrupting ENO1, SU212 starves cancer cells of a critical energy source, thereby crippling their ability to grow and spread. The researchers observed that this process ultimately led to a significant reduction in tumor growth and limited metastasis in sophisticated humanized mouse models of triple-negative breast cancer. These models are genetically engineered to harbor human cancer cells and mimic human disease progression more accurately than traditional animal models, providing a stronger indication of potential efficacy in humans.
"This is an important step forward in our efforts to treat triple-negative breast cancer," stated Dr. Sanjay V. Malhotra, Ph.D., the senior author of the study and co-director of the Center for Experimental Therapeutics in the OHSU Knight Cancer Institute. "Triple-negative breast cancer is an aggressive form of cancer, and the current therapeutic landscape lacks effective targeted drugs. Our findings open a new avenue for intervention by targeting a fundamental metabolic vulnerability of these cells." Dr. Malhotra, who also holds the Sheila Edwards-Lienhart Endowed Chair in Cancer Research and is a professor of cell, developmental, and cancer biology in the OHSU School of Medicine, emphasized the strategic importance of targeting such a ubiquitous enzyme in cancer cell survival.
A Journey of Discovery: From NCI to OHSU
The development of SU212 represents a culmination of years of dedicated research, tracing a chronological path across leading scientific institutions. The compound was originally conceived and developed during Dr. Malhotra’s earlier research tenure at the National Cancer Institute (NCI) in Bethesda, Maryland, a testament to the foundational role of federal funding in groundbreaking scientific discovery. His work on this promising molecule continued and evolved during his time at Stanford University, where his laboratory further refined and studied its properties.
Dr. Malhotra’s arrival at OHSU in 2020 marked a pivotal moment for SU212. OHSU, with its robust infrastructure, collaborative research environment, and a strong commitment to translational medicine through the Knight Cancer Institute and the Center for Experimental Therapeutics, provided the ideal ecosystem for advancing the molecule towards clinical application. The specialized resources, including access to advanced preclinical models and expertise in drug development, enabled the team to rigorously test SU212’s efficacy and mechanism in the context of TNBC. This continuity of research, spanning multiple institutions and years, underscores the persistent effort required to bring a novel therapeutic candidate from initial concept to a validated preclinical stage.
Beyond TNBC: Broad Therapeutic Potential
The implications of SU212’s mechanism of action extend far beyond triple-negative breast cancer. Given that ENO1 plays a critical role in the metabolism of many rapidly proliferating cancer cells, the researchers hypothesize that drugs targeting this enzyme could have a broad therapeutic impact across various cancer types. Preliminary investigations suggest that other aggressive cancers, including glioma (a type of brain cancer), pancreatic cancer, and thyroid carcinoma, are also influenced by ENO1 overexpression or its metabolic pathways.
"A drug that effectively targets enolase 1 could significantly improve the treatment landscape for these other challenging cancers as well," Dr. Malhotra noted. This potential for a pan-cancer approach is particularly exciting for the oncology community. Developing a single drug or drug class that can be applied to multiple cancer types could streamline drug development processes, reduce costs, and accelerate the availability of new treatments for a wider patient population. This strategy represents a paradigm shift from highly specific, receptor-driven therapies to targeting fundamental metabolic vulnerabilities common across diverse malignancies.
The Road Ahead: Clinical Trials and Regulatory Hurdles
While the preclinical findings are highly encouraging, the journey from laboratory discovery to a widely available patient treatment is long and arduous. The immediate next stage of development for SU212 involves moving the molecule toward human clinical trials. This complex process requires substantial resources, meticulous planning, and rigorous adherence to regulatory guidelines set forth by the U.S. Food and Drug Administration (FDA).
The path typically involves several phases:
- Investigational New Drug (IND) Application: Before human trials can begin, researchers must submit an IND application to the FDA, detailing the molecule’s composition, manufacturing, and results from animal studies, along with a proposed plan for human trials.
- Phase 1 Clinical Trials: These initial trials involve a small group of healthy volunteers or patients with advanced disease to assess the drug’s safety, determine a safe dosage range, and identify potential side effects.
- Phase 2 Clinical Trials: If deemed safe, the drug moves to Phase 2, involving a larger group of patients with the target disease to evaluate its effectiveness and further assess safety.
- Phase 3 Clinical Trials: These are large-scale trials comparing the new drug to existing treatments or a placebo in hundreds to thousands of patients, confirming efficacy, monitoring side effects, and collecting information that allows the drug to be used safely.
Each phase can take several years, and the cumulative cost of bringing a new drug to market can run into hundreds of millions, if not billions, of dollars. The high attrition rate of drugs in clinical development means that only a small fraction of promising preclinical candidates ultimately gain FDA approval. Securing the necessary funding from grants, philanthropic donations, and potential pharmaceutical partnerships will be crucial for SU212 to navigate these challenging stages.
Official Reactions and Broader Impact
The scientific community and patient advocacy groups have welcomed OHSU’s announcement with cautious optimism. Leaders at the OHSU Knight Cancer Institute, renowned for its focus on innovative research and patient-centered care, expressed their pride in the team’s achievement. "The work on SU212 exemplifies the core mission of the OHSU Knight Cancer Institute: to revolutionize cancer treatment through groundbreaking discovery and rapid translation to patient care," commented a spokesperson, highlighting the institute’s collaborative environment that fosters such innovations. "We are dedicated to supporting Dr. Malhotra and his team as they work to bring this promising therapy closer to the patients who desperately need it."
Patient advocacy organizations, such as the Triple Negative Breast Cancer Foundation and the Breast Cancer Research Foundation, often emphasize the urgent need for new therapies for TNBC. A representative from a leading advocacy group, speaking generally about such breakthroughs, might state, "Every new molecule, every novel mechanism identified, offers renewed hope for patients and their families grappling with a triple-negative breast cancer diagnosis. While early-stage research, these findings underscore the critical importance of continued investment in scientific research and development to transform the lives of those affected by this aggressive disease."
The research itself was a collaborative effort supported by significant federal funding from the National Cancer Institute, the National Institute of Aging, and the National Heart, Lung and Blood Institute—all components of the National Institutes of Health (NIH). Additional support came from the Department of Defense, the Knight Cancer Institute, the Biomedical Innovation Program at OHSU, and Sheila Edwards-Lienhart endowment funds. These funding bodies play a vital role in enabling high-risk, high-reward research that can lead to transformative medical advances. The success of SU212 highlights the return on investment from public and private funding in biomedical science.
Conclusion: A Beacon of Hope
The development of SU212 by OHSU researchers represents more than just a scientific discovery; it is a beacon of hope for patients with triple-negative breast cancer and potentially other challenging malignancies. By strategically targeting a metabolic vulnerability through the ENO1 enzyme, this molecule offers a novel therapeutic approach where few currently exist. While the path to clinical translation is long and fraught with challenges, the meticulous preclinical work and the compelling findings published in Cell Reports Medicine lay a strong foundation.
As Dr. Malhotra succinctly puts it, "There is definitely great science going on here, and we want to translate that science for the benefit of people." This sentiment encapsulates the driving force behind OHSU’s research enterprise—a commitment to transforming laboratory insights into tangible improvements in human health. The journey of SU212 from an initial concept to a promising therapeutic candidate exemplifies the power of sustained scientific inquiry, collaborative effort, and strategic investment in addressing some of medicine’s most pressing challenges. The global oncology community will be closely watching as SU212 progresses through the rigorous stages of clinical development, holding the promise of a brighter future for countless cancer patients.